Ocular Therapeutix, Inc. (OCUL) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.91: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10 and A.R:R 13.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend.
Ocular Therapeutix is an integrated biopharmaceutical company commercializing DEXTENZA (FDA-approved intracanalicular insert for ocular inflammation) and advancing AXPAXLI, an axitinib intravitreal hydrogel in Phase 3 registrational trials for wet AMD (SOL program) and diabetic... Read more
Sell if holding. Engine safety override at $8.91: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10 and A.R:R 13.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 58. Score 3.9/10, high confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Ocular Therapeutix, Inc.
Latest news
- NEWS Ocular Therapeutix Appoints Jason Robins CFO, Effective June 10 — benzinga Jun 12, 2026 neutral
- NEWS Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Sessi — benzinga May 11, 2026 negative
- NEWS RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target — benzinga May 6, 2026 positive
- NEWS Earnings Scheduled For May 5, 2026 — benzinga May 5, 2026 neutral
- NEWS Ocular Therapeutix Q1 EPS $(0.40) Misses $(0.33) Estimate, Sales $10.785M Miss $12.599M Estimate — benzinga May 5, 2026 negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineAXPAXLI10-K Item 1: 'AXPAXLI...is currently being evaluated in a Phase 3 registrational program for wet age-related macular degeneration...which we refer to as the SOL program. AXPAXLI is currently also being evaluated in a Phase 3 registrational program for diabetic retinal disease...which we refer to as the HELIOS program.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.91: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10 and A.R:R 13.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 58. Prior stop was $8.29. Score 3.9/10, high confidence.
Take-profit target: $22.62 (+153.9% upside). Prior stop was $8.29. Stop-loss: $8.29.
Concentration risk — Pipeline: AXPAXLI; Quality below floor (1.8 < 4.0).
Ocular Therapeutix, Inc. trades at a P/E of N/A (forward -5.6). TrendMatrix value score: 5.4/10. Verdict: Sell.
18 analysts cover OCUL with a consensus score of 4.3/5. Average price target: $26.
What does Ocular Therapeutix, Inc. do?Ocular Therapeutix is an integrated biopharmaceutical company commercializing DEXTENZA (FDA-approved intracanalicular...
Ocular Therapeutix is an integrated biopharmaceutical company commercializing DEXTENZA (FDA-approved intracanalicular insert for ocular inflammation) and advancing AXPAXLI, an axitinib intravitreal hydrogel in Phase 3 registrational trials for wet AMD (SOL program) and diabetic retinal disease (HELIOS program). As of December 31, 2025, it had $737.1 million in cash and $82.5 million in outstanding debt.